Leadstar Bio launches clinical intelligence analysis platform to help research and development of new tumor drugs

The clinical intelligence analysis platform positions the sequencing of precision medicine as whole exome detection + RNA detection.
Exome is all the DNA part of all genes that encodes the proteome, covering more than 24,000 disease-related genes.
(A set or set of tests) refers to several genes that are selected
.

Leadstar Bio will upload the samples of tumor patients to the cloud to analyze mutations after sequencing, and at the same time, automatically generate a result report through the self-built tumor drug database
.
From obtaining clinical samples of cancer patients to reporting to doctors for clinical medication guidance, the overall service delivery cycle can be completed in less than one week
.
Through Leadstar's clinical intelligence analysis platform, patients can obtain more comprehensive medication guidance information faster
.

In addition, the functions of Leadstar's biodata intelligent service have been in the areas of new biomarker/new drug target discovery, mechanism exploration, clinical trial design and prediction, drug combination strategy, precise patient stratification, and expansion of new drug indications.
It has been initially confirmed
.
Since the trial operation in March 2020, Leadstar Bio has signed cooperation agreements with more than 10 companies and reached in-depth cooperation in related businesses
.
The two partners leverage their respective rich experience in knowledge-driven and data-driven drug development to deeply integrate, from the perspective of the combination of efficient clinical drug development and real-world benefits, starting from the end The optimal development and deployment system of new indications for existing innovative drugs and their joint solutions are spawned locally, and jointly promote the intelligent process of accurate clinical drug development
.

In practical applications, the clinical intelligence analysis platform has shown a number of advantages:

• Ability to quickly define and compare patient cohorts;
• A variety of clinical cross-variables can be freely combined to realize visual cohort data analysis;
• Dynamic data analysis, generate survival curve, P value (a parameter used to determine the hypothesis test result), HR ratio and other charts to form enrichment and difference analysis;
• Different from the integrated analysis of data sources, it can realize data integration and linkage;
• The platform is a complete support for data-driven algorithms and highly adaptable clinical bioinformatics
  .
  

The development and use of the clinical intelligence analysis platform is the product of interdisciplinary applications.
The integrated application of comprehensive professional knowledge in the fields of bioinformatics, clinical oncology, genomics, clinical pharmacy, software architecture, artificial intelligence/machine learning and cloud computing , So that the platform can provide scientific and systematic solutions for the research and development of new tumor drugs
.

Innovation is the future development direction and challenge of drug development, and "data + intelligence" is the future opportunity for drug development
.
A new generation of drug R&D companies such as Leadstar Bio will carry out deep cultivation in the field of medical data intelligence to help the research and development of new anti-tumor drugs, and bring well-being to cancer patients in China and the world
.